And more importantly, what does the science say
Kideny J
Rapid proliferation, high protein synthesis rates, hypoxia, nutrient deprivation, acidosis, and oxidative stress collectively impose a severe folding burden on the ER
But Dudum said patients have been getting better care through the compounding process with no greater reporting of issues than the branded drugs and that the FDA tracks all adverse events
In a double-blind phase 2 trial, 157 recruited vitiligo patients were randomized, in a 1:1:1:1:1 ratio, to receive topical ruxolitinib cream 1.5% BID, 1.5% QD, 0.5% QD, 0.15% QD, or a vehicle for 24 weeks, with the result showing considerably decreased CXCL9 and CXCL10 expression in 1.5% BID and 1.5% QD groups, and more individuals in groups receiving ruxolitinib cream 1.5% BID, 1.5% QD and 0.5% QD achieving F-VASI50, during which 1.5% BID group produced the highest responses in F-VASI50 (58%), F-VASI75 (52%), and F-VASI90 (33%)
[10], [11] GHK-Cu exhibits promising analgesic and anti-aggressive effects in rat models, particularly in response to pain-induced aggressive-defensive behavior
